United Therapeutics Corporation (UTHR) Shares are Up 1.38%

United Therapeutics Corporation (UTHR) : Traders are bullish on United Therapeutics Corporation (UTHR) as it has outperformed the S&P 500 by a wide margin of 13.49% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.41%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.38% in the last 1 week, and is up 13.92% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

United Therapeutics Corporation is up 11.71% in the last 3-month period. Year-to-Date the stock performance stands at -18.96%. The stock has recorded a 20-day Moving Average of 3.84% and the 50-Day Moving Average is 11.83%.


United Therapeutics Corporation (NASDAQ:UTHR): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $124.91 and $124.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $127.15. The buying momentum continued till the end and the stock did not give up its gains. It closed at $126.92, notching a gain of 1.03% for the day. The total traded volume was 408,248 . The stock had closed at $125.62 on the previous day.

Also, JP Morgan maintains its view on United Therapeutics Corporation (NASDAQ:UTHR) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. JP Morgan lowers the price target from $145 per share to $129 per share on United Therapeutics Corporation. The rating by the firm was issued on July 29, 2016.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.